Partner With Us
Fostering collaborations to break barriers to innovation
Delivery is the bedrock of gene therapy
Driven by our commitment to transform patient lives, we aim to make gene therapy safer, more effective, and more accessible by developing next-generation delivery technologies that are available for out-licensing. We are on a mission to create a suite of effective tools designed to be highly targeted and applicable to neuromuscular and cardiac indications, and that are supported by extensive preclinical data to help you accelerate development.
Together, we can revolutionize gene therapy.
see "attributes' tool for settings for this row
Introducing POLARIS-101™: Our North Star in Muscle-Targeted Gene Therapy
The same AAV-SLB101 capsid. New identity.
Robust transduction, biodistribution and expression achieved in multiple animal models and in initial participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial (NCT06138639)
Reduced liver biodistribution observed in data from the INSPIRE DUCHENNE clinical trial and in nonclinical studies
Comprehensive preclinical data available to support regulatory discussions and de-risk development
Express MTAs and flexible licensing available to accelerate access for academic and corporate partners
Agreements, including licenses, executed with corporations, institutions and academic labs for use of POLARIS-101™ (AAV-SLB101) announced as of January 13, 2026
Learn more about POLARIS-101™
View recent scientific presentations:
MDA 2026
MDA 2026
MDA 2026
ASGCT 2025
ASGCT 2025
ASGCT 2025
NMSG 2025
ESGCT 2025
CVCT 2025
View corporate presentation:
Therapeutic
We are advancing programs in syndromic and non-syndromic cardiac conditions as well as muscular and neuromuscular skeletal diseases. While these are priority areas, we remain open to innovative and transformative opportunities beyond cardiac and skeletal. We are particularly interested in programs that go beyond single-gene corrections and offer scalable potential across multiple conditions. Lead or development-stage assets are preferred, though we are open to earlier-stage platform technologies.
Immunomodulatory Strategies
We are exploring novel approaches to overcome immune challenges that currently limit the reach of gene therapies. This includes strategies to enable redosing, address pre-existing immunity (e.g., AAV seropositivity), and improve safety and efficacy. We welcome partners developing tools or technologies that modulate immune responses to broaden patient access and enhance therapeutic durability.
Innovative Delivery Technologies
We are seeking advanced delivery platforms—both viral and non-viral—that improve tissue targeting, overcome biological barriers, and enhance therapeutic precision. Areas of interest include LNPs, engineered capsids, and other novel vehicles capable of delivering genetic medicines efficiently to muscle, heart, and beyond. We are also interested in manufacturing-enabling technologies that reduce costs and improve scalability.